A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Daily Oral NYX2925 in Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Daily Oral NYX2925 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2017

At a glance

  • Drugs NYX 2925 (Primary)
  • Indications Neurological disorders
  • Focus Adverse reactions; First in man
  • Sponsors Aptinyx
  • Most Recent Events

    • 17 May 2017 According to an Aptinyx media release, the company expects to report the results from the study, next month.
    • 04 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2017 Planned number of patients changed from 70 to 84.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top